Modern potentials for use of candesartan in prevention and treatment of cardiovascular diseas


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Sartans represent a relatively new group of antihypertensive drugs, but their effectiveness is well documented in many clinical situations. Candesartan is one of the most studied sartans; it has a strong and long-lasting antihypertensive effect. Candesartan's advantage compared to other drugs of the same group includes favorable pharmacokinetic profile. Candesartan has proved effectiveness in treating prehypertension, reduction of left ventricular hypertrophy, protection from stroke, slowing of the progression of chronic heart failure, and prevention of the development of paroxysmal atrial fibrillation. These properties of candesartan were confirmed in a number of clinical studies.

Full Text

Restricted Access

About the authors

Galina A. Batishcheva

N.N. Burdenko Voronezh State medical university

MD, professor, head of the Department of clinical pharmacology

Olga A. Mubarakshina

N.N. Burdenko Voronezh State medical university

Email: mubarakshina@mail.ru
PhD, assistant of the Department of clinical pharmacology

Marina N. Somova

N.N. Burdenko Voronezh State medical university

Email: somova_marina@inbox.ru
PhD, associate professor of the Department of clinical pharmacology

Anastasiya S. Yevstigneeva

N.N. Burdenko Voronezh State medical university

clinical intern of the Department of clinical pharmacology

References

  1. Шальнова С.А., Деев А.Д. Характеристика пациентов высокого риска. Результаты эпидемиологической части научно-образовательной программы ОСКАР. Кардиоваскулярная терапия и профилактика. 2006;6:58-63
  2. Kannel W.B., Dawler T.R., Mac Gee D.L. Perspectives on systolic hypertension: the Framingham Study. Circulation. 1985;61:1 179-82.
  3. Bavishi C., Bangalore S., Messerli F.H. Renin angiotensin aldosterone system inhibitors in hypertension: is there evidence for benefit independent of blood pressure reduction? Prog. Cardiovasc. Dis. 2016;59(3):253-61.
  4. Kizilirmak P., Üresin Y., Özdemir O., Kiliçkiran Avci B., Tokgözoglu L., Öngen Z. Renin-angiotensin-aldosterone system blockers and cardiovascular outcomes: a meta-analysis of randomized clinical trials. Turk. Kardiyol. Dern. Ars. 2017;45(1):49-66.
  5. Сидоренко Б.А., Преображенский Д.В. Ингибиторы ангиотензинпревращающего фермента. М.: Информатик, 1999. c. [Sidorenko B.A., Preobrazhensky D.V. Inhibitors of angiotensin converting ferment. Moscow: Science, 1999. 253 p. (in Russ.)]
  6. Мунгер М.А. Терапия блокаторами рецепторов ангиотензина и кардиоваскулярная протекция. Современная доказательная база и перспективы развития. Кардиоваскулярная терапия и профилактика. 2011;10(7):93-104. [Munger M.A. Therapy with blockers of receptors of angiotensin and cardiovascular protection. Modern evidence base and development prospects. Cardiovascular therapy and prevention. 2011;10(7):93-104 (in Russ.)]
  7. Остроумова О.Д., Максимов М.Л., Щукина Г.Н., Шорникова Е.Г. Антагонисты рецепторов к ангиотензину II в 2010 г., что нового? Системные гипертензии. 2011;1:2-5. [Ostroumova O.D., Maksimov M.L., Shchukina G.N., Shornikova Ye.G. Angiotensin-II receptor antagonists in 2010, what's new? Systemic hypertensions. 2011;1:2-5 (in Russ.)]
  8. Стуров Н.В. Органопротективные свойства блокаторов рецепторов ангиотензина II (сартанов). Справочник поликлинического врача. 2009;8:31-4. [Sturov N.I. Organ protective properties of angiotensin-II receptor antagonists (sartans). Directory of outpatient physician. 2009;8:31-4 (in Russ.)]
  9. Гиляревский С.Р., Голшмид М.В., Кузьмина И.М. Доказательная история кандесартана: прошлое, будущее и настоящее. Сердечная недостаточность. 2015;16(5):303-10. [Gilyarevsky R.S., Goldshmid M.V., Kuzmina I.M. Evidence-based candesartan in history: past, present and future. Heart failure. 2015;16(5):303-10 (in Russ.)]
  10. Julius S., Nesbitt S.D., Egan B.M., Weber M.A., Michelson E.L., Kaciroti N., Black H.R., Grimm R.H. Jr, Messerli F.H., Oparil S., Schork M.A.; Trial of Preventing Hypertension (TROPHY) Study Investigators. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N. Engl. J. Med. 2006;354:1685-97.
  11. Williams S.A., Michelson E.L., Cain V.A., Yang M., Nesbitt S.D., Egan B.M., Julius S.; TROPHY Study Investigators. An evaluation of the effects of an angiotensin receptor blocker on health-related quality of life in patients with high-normal blood pressure (prehypertension) in the Trial of Preventing Hypertension (TROPHY). J. Clin. Hypertens (Greenwich). 2008;10:436-42.
  12. Lithell H., Hansson L., Skoog I., Elmfeldt D., Hofman A., Olofsson B., Trenkwalder P., Zanchetti A.; SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J. Hypertens. 2003;21(5):875-86.
  13. Degl'Innocenti A., Elmfeldt D., Hofman A., Lithell H., Olofsson B., Skoog I., Trenkwalder P., Zanchetti A., Wiklund I. Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). J. Hum. Hypertens. 2004;18(4):239-45.
  14. Papademetriou V., Farsang C., Elmfeldt D., Hofman A., Lithell H., Olofsson B., Skoog I., Trenkwalder P., Zanchetti A.; Study on Cognition and Prognosis in the Elderly study group. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J. Am. Coll. Cardiol. 2004;44(6):1 175-80.
  15. Trenkwalder P., Elmfeldt D., Hofman A., Lithell H., Olofsson B., Papademetriou V., Skoog I., Zanchetti A.; The Study on COgnition and Prognosis in the Elderly (SCOPE). The Study on COgnition and Prognosis in the Elderly (SCOPE) - major CV events and stroke in subgroups of patients. Blood Press. 2005;14(1):31-7.
  16. Lithell H., Hansson L., Skoog I., Elmfeldt D., Hofman A., Olofsson B., Trenkwalder P., Zanchetti A.; SCOPE Study Group. The Study on COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. J. Hypertens. 2004;22(8):1605-12.
  17. Skoog I., Lithell H., Hansson L., Elmfeldt D., Hofman A., Olofsson B., Trenkwalder P., Zanchetti A.; SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). Am. J. Hypertens. 2005;18(8):1052-9.
  18. Saxby B.K., Harrington F., Wesnes K.A., McKeith I.G., Ford G.A. Candesartan and cognitive decline in older patients with hypertension: a substudy of the SCOPE trial. Neurology. 2008;70(19 Pt. 2):1858-66.
  19. Kjeldsen S.E., Stalhammar J., Hasvold P., Bodegard J., Olsson U., Russell D. Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension. J. Hum. Hypertens. 2010;24(4):263-73.
  20. Отчет о результатах исследования CNDN-01 «Открытое рандомизированное перекрестное исследование сравнительной фармакокинетики и биоэквивалентности препаратов Гипосарт, таблетки 32 мг, Фармацевтический завод «Польфарма» АО (Польша), и Атаканд, таблетки 32 мг, «АстраЗенека АБ» (Швеция), с участием здоровых добровольцев». Москва, 2013. [Report on the results of the study CNDN-01 "open-label randomized cross-overing the study of comparative pharmacokinetics and bioequivalence of drugs Hyposart, tablets 32 mg, pharmaceutical factory "Polpharma" (Poland), and Atakand, tablets 32 mg, "AstraZeneca AB" (Sweden), with the participation of healthy volunteers". Moscow, 2013 (in Russ.)]

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies